12 16 20 24 1 10 100 1000 10000 100000 Durability: Zenkuda achieved an extended ocular half-life of >20 days in 45% of sampled patients from the Phase 1b Study All Patients (n=47) Tarcocimab aqueous humor concentration (ng/ml) t 1/2 = 6.1 days t 1/2 = 10.1 days t 1/2 = 16.9 days t 1/2 = 27.5 days Select Individual Patients * 19% 36% 45% Patients Ocular t½ Distribution (N=47) >20 Days 11-20 Days ≤11 Days t 1/2 = 39.8 days 12 16 20 24 1 10 100 1000 10000 100000 Each line represents one individual patient from the Phase 1b study of Zenkuda in patients with wAMD, DME and RVO. N= 47 patients, all received an intravitreal injection of 5mg Zenkuda clinical formulation on day 1. *Mean and standard deviations are plotted, though SDs are not visible due to small magnitude 15